Which test is required to diagnose hepatic steatosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Diagnostic Testing for Hepatic Steatosis

Abdominal ultrasonography is the primary screening test for diagnosing hepatic steatosis 1, 2, 1.

First-Line Diagnostic Approach

Ultrasound serves as the initial diagnostic modality because it offers robust diagnostic performance for moderate-to-severe steatosis (>30% fat content), wide availability, low cost, and the ability to evaluate the entire hepatobiliary system simultaneously 1, 2. The 2023 ACR Appropriateness Criteria and 2021 KASL guidelines both designate ultrasound as the first-line investigation tool 2, 1.

Ultrasound Performance Characteristics

Standard ultrasound demonstrates:

  • 84.8% sensitivity and 93.6% specificity for moderate-to-severe hepatic steatosis (>30% fat) 2
  • Reduced accuracy for mild steatosis: sensitivity drops to 53.3-65% and specificity to 77-81.2% when mild steatosis is included 2
  • Cannot detect steatosis <30% reliably 1

The hepatorenal index (quantitative ultrasound measurement comparing liver to kidney echogenicity) shows excellent correlation with MR spectroscopy and liver biopsy, with AUC up to 99.2-99.6% for mild steatosis, and remains independent of confounding factors like obesity, inflammation, or fibrosis 2.

Advanced Imaging When Needed

MRI-Proton Density Fat Fraction (MRI-PDFF)

MRI-PDFF is the most accurate non-invasive method for detecting and quantifying hepatic steatosis 3, 4. However, guidelines explicitly state it should not be used as first-line due to cost and limited availability 4.

MRI-PDFF demonstrates:

  • AUC of 0.98 for mild or worse steatosis
  • AUC of 0.91 for moderate or worse steatosis
  • AUC of 0.90 for severe steatosis 3
  • Can accurately diagnose steatosis as low as 5% fat content 2

Reserve MRI-PDFF for: clinical trials, when ultrasound is inconclusive, or when precise quantification is required for treatment monitoring 4.

Controlled Attenuation Parameter (CAP)

CAP via transient elastography quantifies liver fat by measuring ultrasound attenuation 1. While promising, CAP cannot yet be recommended as first-line given limited availability and lack of head-to-head studies versus ultrasound 4.

CAP performance:

  • Cutoff >275 dB/m shows >90% sensitivity for detecting steatosis 4
  • AUC of 0.96,0.82, and 0.70 for mild, moderate, and severe steatosis respectively 1
  • Can be performed simultaneously with liver stiffness measurement 1

CT Scanning

CT is NOT recommended for first-line diagnosis 2. Unenhanced CT shows 100% specificity but only 53.8% sensitivity for moderate-to-severe steatosis, and performs poorly for mild steatosis 1. Additionally, CT involves radiation exposure and is affected by iron, copper, or other material deposition in the liver 1.

Clinical Algorithm

  1. Start with abdominal ultrasound for all patients with suspected hepatic steatosis 1, 4

  2. If ultrasound shows moderate-to-severe steatosis: diagnosis confirmed; proceed with fibrosis assessment and metabolic workup

  3. If ultrasound is negative but clinical suspicion remains high (diabetes, obesity, metabolic syndrome): consider CAP if available, or MRI-PDFF for definitive assessment 1

  4. If precise quantification needed (clinical trials, treatment monitoring): use MRI-PDFF 4

Critical Caveats

  • Ultrasound has significant limitations: subjective interpretation, inter-observer variability, difficulty in obese patients, and cannot distinguish simple steatosis from steatohepatitis 1
  • Blood-based scores are NOT recommended for diagnosing steatosis in clinical practice 4
  • Liver biopsy remains the gold standard for definitive diagnosis and is the only method that can differentiate bland steatosis from steatohepatitis, but its invasive nature limits routine use 1
  • Ultrasound specificity deteriorates with confounding factors like inflammation or fibrosis 2

References

2
Guideline

acr appropriateness criteria® abnormal liver function tests.

Journal of the American College of Radiology, 2023

Related Questions

What is the appropriate evaluation and management for a 66-year-old female with hepatic steatosis and hepatomegaly identified on abdominal ultrasound?
What does grade 2 fatty liver (moderate steatosis) mean?
What is the recommended management for hepatic steatosis and atelectasis?
How is fatty liver diagnosed?
In a 53-year-old male with hepatomegaly and hepatic steatosis on ultrasound, what follow-up is recommended and should he be referred to gastroenterology?
Does Horner syndrome occur on the same side as a lung lesion (e.g., a Pancoast tumor)?
What target weight should be achieved before stopping Mounjaro (tirzepatide)?
What is the most likely diagnosis for a stable patient presenting with fever and large, non‑painful, bruise‑like purpuric lesions over the body?
Should an afebrile, ambulatory patient be admitted and started on empiric intravenous ceftriaxone for possible meningococcal infection?
Is the FibroSure (FibroTest) blood test appropriate for diagnosing fatty liver disease and assessing liver fibrosis?
Can fearfulness occur in hepatic encephalopathy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.